

Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Integrated Care Partnership - Surrey Downs, Guildford & Waverley, North West Surrey, and
East Surrey Places & associated partner organisations

APC application front coversheet – to accompany all applications to the APC

Title of paper:	Update PAD narrative for Lotemax Eye drops
Meeting date:	tbc
Author and contributors:	Georgina Randall, Senior Pharmacy Technician, Medicine Resource Unit, NHS Surrey Heartlands ICB
Paper type	Front cover
For:	Approval
<p>Executive Summary: <i>(provide a short description of the subject matter and draw attention to the relevant issues/facts for the attention of the APC.</i></p> <p>In October 2006, the following information was published on the Surrey PAD :(https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/4482).</p> <p>Lotemax® (loteprednol etabonate) eye drops was awarded a RED traffic light status, and it is assumed that this status was awarded due to:</p> <ol style="list-style-type: none"> 1. The product is indicated for the treatment of post-operative inflammation following ocular surgery and therefore sufficient quantities should be provided by the trust as part of the package of care. 2. The product license stating that the duration of treatment should not exceed 2 weeks. <p>This continues to remain in effect, see Summary of Product Characteristics (SmPC) for Lotemax : (https://www.medicines.org.uk/emc/product/6212/smpc#gref) - “(Adults and elderly only) - One to two drops four times daily beginning 24 hours after surgery and continuing throughout the post-operative period. The duration of treatment should not exceed 2 weeks”.</p> <p>However in 2017, Sussex CCG/ICB awarded a PURPLE traffic light status (equivalent to BLUE traffic light status in Surrey Heartlands) to Lotemax and this discrepancy between Surrey Heartlands and Sussex continues to cause problems and queries in primary care. It is not clear as to why Sussex are allowing this use, which is in effect off-label, but it could be being used to facilitate patient access to a low potency steroid in corneal transplant patients that require at least 2 years of treatment.</p> <p>The Medicine Resource Unit propose that the PAD narrative is re-worded to make it very clear to prescribers as to why a RED traffic light status continues to be in place in the Surrey Heartlands ICB geography in the hopes that this will reduce the number of prescribing problems and queries in the future.</p> <p>If there is a need to consider loteprednol for corneal transplant patients (off-label indication), this will be subject to a separate application to APC.</p>	
<p>Actions for the APC: <i>(summarise what the APC is being asked to do and why)</i></p> <ul style="list-style-type: none"> • Agree proposed re-worded PAD narrative as below. <p>“The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) agrees that Loteprednol etabonate eye drops (Lotemax®) should only be used on a short-term</p>	

basis (maximum of 2 weeks duration) to treat post-operative inflammation as per its product license. Therefore loteprednol is awarded a RED traffic light status. Sufficient quantities should only be supplied through secondary care as part of a package of post-operative care.”

Accompanying papers:

1. None.